Goals of this study include:
- Explore which circulating endocrine markers or endocrine related markers have the best
potential to predict clinical response to abiraterone acetate in CRPC patients
- Explore the utility of microRNA, circulating DNA and exosome analyses in complementing
the previous objective
Observational
Observational Model: Case Control, Time Perspective: Prospective
PSA
PSA nadir samples will be assessed and compared to pre-Abiraterone treatment samples post completion of study
Patients will be followed from Day 1 (date of initiation of Abiraterone treatment) until the date of first documented progression (estimated to be 1 year). PSA will be assessed every 30 days (approximately) until the time of PSA/clinical progression
No
Anthony Joshua, BSc(Med) MBBS PhD FRACP
Principal Investigator
Princess Margaret Cancer Centre
Canada: Ethics Review Committee
ABI Correlative Study
NCT01857908
June 2012
December 2013
Name | Location |
---|